Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.02 USD
Change Today +0.05 / 2.54%
Volume 591.4K
PTIE On Other Exchanges
PTIE is not on other exchanges.
As of 5:20 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Announces Positive Results from Drug Abuse Study

Pain Therapeutics Inc. announced positive results from an FDA Category 3 Human Abuse Potential Study with REMOXY extended-release capsules CII, which is designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p < 0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.

Pain Therapeutics Inc. - Special Call

To discuss progress across its portfolio of drug candidates and to respond to questions

Pain Therapeutics Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Pain Therapeutics Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $2,595,000 against $3,464,000 a year ago. Interest income was $12,000 against $14,000 a year ago. Net loss was $2,583,000 or $0.06 basic and diluted per share against $3,450,000 or $0.08 basic and diluted per share a year ago.

Pain Therapeutics Announces Appointment of Michael Marsman as Senior Vice President, Regulatory Affairs

Pain Therapeutics Inc. announced the appointment of Michael Marsman, Pharm.D., as Senior Vice President, Regulatory Affairs. Dr. Marsman will be responsible for developing and implementing regulatory strategies to gain drug approvals. He previously led regulatory affairs at Pain Therapeutics for nearly a decade before leaving in 2012 amid a corporate reorganization. Dr. Marsman most recently served as V.P. Regulatory Affairs at Impax Laboratories.

Pain Therapeutics Inc., Annual General Meeting, May 14, 2015

Pain Therapeutics Inc., Annual General Meeting, May 14, 2015., at 10:00 Central Standard Time. Location: 7801 N Capital of Texas Highway. Agenda: To elect Remi Barbier, Sanford R. Robertson and Patrick J. Scannon, M.D., Ph.D. as Class III Directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2015; to approve, by a non-binding advisory vote, the 2014 executive compensation for the company’s executive officers; and to transact such other business as may properly be brought before the meeting and any adjournment(s) thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $2.02 USD +0.05

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies

Industry Analysis


Industry Average

Valuation PTIE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at